Smith & Nephew SNATS Debt to Equity Ratio 2012-2025 | SNN
Current and historical debt to equity ratio values for Smith & Nephew SNATS (SNN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Smith & Nephew SNATS debt/equity for the three months ending December 31, 2025 was 0.60.
| Smith & Nephew SNATS Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-12-31 | $5.17B | $5.29B | 0.98 |
| 2025-06-30 | $5.16B | $5.54B | 0.93 |
| 2024-12-31 | $5.09B | $5.27B | 0.97 |
| 2024-06-30 | $5.34B | $5.21B | 1.03 |
| 2023-12-31 | $4.77B | $5.22B | 0.91 |
| 2023-06-30 | $4.61B | $5.23B | 0.88 |
| 2022-12-31 | $4.71B | $5.26B | 0.90 |
| 2022-06-30 | $4.71B | $5.40B | 0.87 |
| 2021-12-31 | $5.35B | $5.57B | 0.96 |
| 2021-06-30 | $5.60B | $5.33B | 1.05 |
| 2020-12-31 | $5.73B | $5.28B | 1.09 |
| 2020-06-30 | $4.58B | $4.96B | 0.92 |
| 2019-12-31 | $4.16B | $5.14B | 0.81 |
| 2019-06-30 | $3.99B | $4.95B | 0.81 |
| 2018-12-31 | $3.19B | $4.87B | 0.65 |
| 2018-06-30 | $3.07B | $4.64B | 0.66 |
| 2017-12-31 | $3.22B | $4.64B | 0.69 |
| 2017-06-30 | $3.24B | $4.20B | 0.77 |
| 2016-12-31 | $3.39B | $3.96B | 0.86 |
| 2015-12-31 | $3.20B | $3.97B | 0.81 |
| 2015-06-30 | $3.17B | $4.05B | 0.78 |
| 2014-12-31 | $3.27B | $4.04B | 0.81 |
| 2014-09-30 | $3.63B | $4.02B | 0.90 |
| 2014-06-30 | $3.59B | $4.16B | 0.86 |
| 2014-03-31 | $1.72B | $4.22B | 0.41 |
| 2013-12-31 | $1.77B | $4.05B | 0.44 |
| 2013-09-30 | $1.66B | $3.91B | 0.42 |
| 2013-06-30 | $1.56B | $3.90B | 0.40 |
| 2013-03-31 | $1.51B | $3.95B | 0.38 |
| 2012-12-31 | $1.76B | $3.88B | 0.45 |
| 2012-09-30 | $1.36B | $3.64B | 0.37 |
| 2012-06-30 | $1.26B | $3.56B | 0.35 |
| 2012-03-31 | $1.43B | $3.45B | 0.41 |
| 2011-12-31 | $1.56B | $3.19B | 0.49 |
| 2011-09-30 | $1.76B | $3.06B | 0.58 |
| 2011-06-30 | $1.78B | $3.13B | 0.57 |
| 2011-03-31 | $1.79B | $3.00B | 0.60 |
| 2010-12-31 | $1.96B | $2.77B | 0.71 |
| 2010-09-30 | $2.40B | $2.48B | 0.97 |
| 2010-06-30 | $2.27B | $2.31B | 0.98 |
| 2010-03-31 | $2.31B | $2.23B | 1.04 |
| 2009-12-31 | $2.39B | $2.18B | 1.10 |
| 2009-09-30 | $2.62B | $2.01B | 1.30 |
| 2009-06-30 | $2.64B | $1.88B | 1.40 |
| 2009-03-31 | $2.60B | $1.71B | 1.52 |
| 2008-12-31 | $2.81B | $1.70B | 1.65 |
| 2008-09-30 | $2.75B | $1.77B | 1.55 |
| 2008-06-30 | $2.90B | $1.81B | 1.61 |
| 2008-03-31 | $2.87B | $1.81B | 1.59 |
| 2007-12-31 | $2.63B | $1.82B | 1.45 |
| 2007-09-30 | $2.37B | $1.91B | 1.25 |
| 2007-06-30 | $2.08B | $2.16B | 0.96 |
| 2007-03-31 | $1.06B | $2.16B | 0.49 |
| 2006-12-31 | $1.06B | $2.17B | 0.49 |
| 2006-09-30 | $1.13B | $2.07B | 0.55 |
| 2006-06-30 | $1.15B | $2.01B | 0.57 |
| 2006-03-31 | $1.21B | $1.89B | 0.64 |
| 2005-12-31 | $1.62B | $1.57B | 1.03 |
| 2005-09-30 | $1.55B | $1.43B | 1.08 |
| 2005-06-30 | $1.65B | $1.44B | 1.15 |
| 2005-03-31 | $1.60B | $1.42B | 1.13 |
| 2004-12-31 | $1.38B | $1.33B | 1.04 |
| 2004-09-30 | $1.19B | $1.35B | 0.88 |
| 2004-06-30 | $1.19B | $1.28B | 0.93 |
| 2004-03-31 | $1.20B | $1.25B | 0.96 |
| 2003-12-31 | $1.08B | $1.14B | 0.94 |
| 2003-09-30 | $0.00B | 0.00 | |
| 2003-06-30 | $0.00B | 0.00 | |
| 2003-03-31 | $0.00B | 0.00 | |
| 2002-12-31 | $1.16B | $0.83B | 1.39 |
| 2001-12-31 | $1.01B | $0.59B | 1.71 |
| 2000-12-31 | $1.04B | $0.40B | 2.59 |
| 1999-12-31 | $0.69B | $0.89B | 0.78 |
| 1998-12-31 | $0.70B | $0.81B | 0.87 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $14.227B | $6.164B |
| Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |